{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["887"],"submitter":["Hushmandi K"],"pubmed_abstract":["In December 2019, an unprecedented outbreak of pneumonia associated with a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The virus that caused the disease was officially named by the World Health Organization (WHO) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the high transmission rate of SARS-CoV-2, it became a global pandemic and public health emergency within few months. Since SARS-CoV-2 is genetically 80% homologous with the SARS-CoVs family, it is hypothesized that medications developed for the treatment of SARS-CoVs may be useful in the control and management of SARS-CoV-2. In this regard, some medication being tested in clinical trials and in vitro studies include anti-viral RNA polymerase inhibitors, HIV-protease inhibitors, anti-inflammatory agents, angiotensin converting enzyme type 2 (ACE 2) blockers, and some other novel medications. In this communication, we reviewed the general characteristics of medications, medical usage, mechanism of action, as well as SARS-CoV-2 related trials."],"journal":["European journal of pharmacology"],"pagination":["173568"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7501068"],"repository":["biostudies-literature"],"pubmed_title":["A review of medications used to control and improve the signs and symptoms of COVID-19 patients."],"pmcid":["PMC7501068"],"pubmed_authors":["Hashemi F","Raei M","Habtemariam S","Moghadam ER","Nabavi SM","Hashemi M","Bagheri M","Hushmandi K","Bokaie S"],"additional_accession":[]},"is_claimable":false,"name":"A review of medications used to control and improve the signs and symptoms of COVID-19 patients.","description":"In December 2019, an unprecedented outbreak of pneumonia associated with a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan City, Hubei province, China. The virus that caused the disease was officially named by the World Health Organization (WHO) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the high transmission rate of SARS-CoV-2, it became a global pandemic and public health emergency within few months. Since SARS-CoV-2 is genetically 80% homologous with the SARS-CoVs family, it is hypothesized that medications developed for the treatment of SARS-CoVs may be useful in the control and management of SARS-CoV-2. In this regard, some medication being tested in clinical trials and in vitro studies include anti-viral RNA polymerase inhibitors, HIV-protease inhibitors, anti-inflammatory agents, angiotensin converting enzyme type 2 (ACE 2) blockers, and some other novel medications. In this communication, we reviewed the general characteristics of medications, medical usage, mechanism of action, as well as SARS-CoV-2 related trials.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-04T10:55:48.7Z","creation":"2020-09-28T07:02:11Z"},"accession":"S-EPMC7501068","cross_references":{"pubmed":["32956644"],"doi":["10.1016/j.ejphar.2020.173568"]}}